When.com Web Search

  1. Ads

    related to: reasons not to take tamoxifen for women over 65 days

Search results

  1. Results From The WOW.Com Content Network
  2. BRCA mutation - Wikipedia

    en.wikipedia.org/wiki/BRCA_mutation

    Women with a breast cancer associated with a BRCA mutation have up to a 40% probability of developing a new primary breast cancer within 10 years following initial diagnosis if they did not receive tamoxifen treatment or have an oophorectomy. [4] The woman's ten-year risk for ovarian cancer is also increased by 6-12% under these conditions. [4]

  3. Shannen Doherty Once 'Believed' IVF Treatments Caused ... - AOL

    www.aol.com/entertainment/shannen-doherty-once...

    She recalled why she rejected Piro’s suggestion to take Tamoxifen, a drug that has been shown to reduce the chance of breast cancer in women who are high-risk, after going into remission in 2017.

  4. Tamoxifen - Wikipedia

    en.wikipedia.org/wiki/Tamoxifen

    Updated results after an average of 6.75 years of follow up found that raloxifene retains 76% of tamoxifen's effectiveness in preventing invasive breast cancer, with 45% fewer uterine cancers and 25% fewer blood clots in women taking raloxifene than in women taking tamoxifen. [30] [31] [32]

  5. Breast cancer - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer

    This is an accepted version of this page This is the latest accepted revision, reviewed on 29 January 2025. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Surgical Oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on ...

  6. Most women older than 65 don't need to stop hormone therapy ...

    www.aol.com/lifestyle/most-women-older-65-dont...

    Now, new research finds that women who use hormone therapy after age 65 are usually fine to do just that — but the dose and timing of the treatment matter. The study, which was published in ...

  7. Selective estrogen receptor modulator - Wikipedia

    en.wikipedia.org/wiki/Selective_estrogen...

    Tamoxifen is more promiscuous than raloxifene in target sites because of the relationship between ER's amino acid in Asp-351 and the antiestrogenic side chain of the SERM. The side chain for tamoxifen cannot neutralize Asp-351, so the site allosterically influences AF-1 at the proximal end of the ER. This issue is mended with the second ...